[go: up one dir, main page]

PH12017501184A1 - Pharmaceutical composition for treating diabetes - Google Patents

Pharmaceutical composition for treating diabetes

Info

Publication number
PH12017501184A1
PH12017501184A1 PH12017501184A PH12017501184A PH12017501184A1 PH 12017501184 A1 PH12017501184 A1 PH 12017501184A1 PH 12017501184 A PH12017501184 A PH 12017501184A PH 12017501184 A PH12017501184 A PH 12017501184A PH 12017501184 A1 PH12017501184 A1 PH 12017501184A1
Authority
PH
Philippines
Prior art keywords
pharmaceutical composition
treating diabetes
dpp
inhibitor
metformin
Prior art date
Application number
PH12017501184A
Other versions
PH12017501184B1 (en
Inventor
Eon-Pyo Hong
Dong-Wook Kim
Hye-Suk Hong
Jin-Keon Pai
Original Assignee
Handok Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53500898&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12017501184(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Handok Inc filed Critical Handok Inc
Publication of PH12017501184A1 publication Critical patent/PH12017501184A1/en
Publication of PH12017501184B1 publication Critical patent/PH12017501184B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition for treating diabetes, containing metformin and a DPP-TV inhibitor. The pharmaceutical composition for treating diabetes according to the present invention can cut off the contact between the DPP-TV inhibitor and metformin, so that the lifespan of the composition is increased and the amount as well as the kind of a flexible material contained in the composition is reduced. Furthermore, the DPP-TV inhibitor can be rapidly released and the sustained-release of metformin can be controlled.
PH12017501184A 2014-12-23 2017-06-22 Pharmaceutical composition for treating diabetes PH12017501184B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140186677A KR101526825B1 (en) 2014-12-23 2014-12-23 Pharmaceutical Compositions for The Treatment of Diabetes
PCT/KR2015/014096 WO2016105084A2 (en) 2014-12-23 2015-12-22 Pharmaceutical composition for treating diabetes

Publications (2)

Publication Number Publication Date
PH12017501184A1 true PH12017501184A1 (en) 2017-12-18
PH12017501184B1 PH12017501184B1 (en) 2021-11-05

Family

ID=53500898

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017501184A PH12017501184B1 (en) 2014-12-23 2017-06-22 Pharmaceutical composition for treating diabetes

Country Status (7)

Country Link
KR (1) KR101526825B1 (en)
CN (1) CN107205969B (en)
MY (1) MY196438A (en)
PH (1) PH12017501184B1 (en)
SG (1) SG11201705194XA (en)
TW (1) TW201628602A (en)
WO (1) WO2016105084A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106421794A (en) * 2016-09-27 2017-02-22 黑龙江珍宝岛药业股份有限公司 Drug compound for treating type II diabetes and preparation method thereof
WO2019066359A2 (en) * 2017-09-29 2019-04-04 한미약품 주식회사 Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin
KR102500835B1 (en) * 2017-10-24 2023-02-17 한미약품 주식회사 Complex Preparations Comprising Lingliptin and Metformin as an active ingredients and preparing method thereof
TR201721824A2 (en) * 2017-12-26 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A MODIFIED EMISSION COMBINATION CONTAINING LINAGLIPTIN AND METFORMIN
CN113116842A (en) * 2019-12-31 2021-07-16 广州玻思韬控释药业有限公司 Stomach retention tablet
KR20230051096A (en) * 2021-10-08 2023-04-17 (주)셀트리온 Pharmaceutical composition for treatment of diabetes with improved stability
CN115715768B (en) * 2022-11-24 2024-07-05 浙江昂利泰制药有限公司 Small sitagliptin-metformin sustained-release tablet and preparation method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100705210B1 (en) * 2004-09-23 2007-04-06 주식회사 한독약품 Pharmaceutical combinations for the treatment of diabetes for oral administration
KR100760430B1 (en) * 2004-12-31 2007-10-04 한미약품 주식회사 Sustained release combination preparations for oral administration of a diabetes treatment and preparation method thereof
DK1894567T3 (en) * 2005-06-03 2012-11-19 Mitsubishi Tanabe Pharma Corp Accompanying pharmaceuticals and their use
US8414921B2 (en) * 2005-12-16 2013-04-09 Merck Sharp & Dohme Corp. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
CN101168059A (en) * 2007-10-12 2008-04-30 重庆医药工业研究院有限责任公司 Stable medicinal composition containing biguanide, sulfonylurea and thiazolidinedione and preparation method thereof
CN101168060B (en) * 2007-10-12 2012-06-13 重庆医药工业研究院有限责任公司 Stable medicinal composition containing biguanide and sulfonylurea and preparation method thereof
CA2713361A1 (en) * 2008-02-05 2009-08-13 Merck Sharp & Dohme Corp. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
MX2011008416A (en) * 2009-02-13 2011-09-08 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics.
JP6042330B2 (en) * 2010-07-09 2016-12-14 ビーエイチヴィ ファーマ、インコーポレイテッド Combined immediate / delayed delivery system for short half-life drugs including remogliflozin
UY33937A (en) * 2011-03-07 2012-09-28 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
KR101409330B1 (en) * 2012-05-11 2014-06-18 안국약품 주식회사 Sustained-Release combination preparations for the treatment of diabetes mellitus having enhanced compliance and preparation method thereof
KR20140013436A (en) * 2012-07-24 2014-02-05 한미약품 주식회사 Composite formulation for oral administration comprising metformin and rosuvastatin
CN103285398B (en) * 2013-06-28 2015-07-22 青岛黄海制药有限责任公司 Compound preparation containing DPP-IV (dipeptidyl peptidase-IV) inhibitor and type-II diabetes medicine and preparation method thereof

Also Published As

Publication number Publication date
WO2016105084A3 (en) 2016-09-09
CN107205969B (en) 2020-06-30
PH12017501184B1 (en) 2021-11-05
CN107205969A (en) 2017-09-26
WO2016105084A2 (en) 2016-06-30
KR101526825B1 (en) 2015-06-08
SG11201705194XA (en) 2017-07-28
MY196438A (en) 2023-04-11
TW201628602A (en) 2016-08-16

Similar Documents

Publication Publication Date Title
PH12017501184A1 (en) Pharmaceutical composition for treating diabetes
CL2016003075A1 (en) Composition for treating diabetes, which contains a long-acting insulin analogue conjugate and a long-acting insulinotropic peptide conjugate
PL3438076T3 (en) Use of type of compounds as energetic material
EA033325B1 (en) Bromodomain inhibitors
MX2022003859A (en) Treatment of retinitis pigmentosa.
AU2015208932A8 (en) (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase I inhibitors
ZA201800015B (en) Material for enhancing attributes of a topical or surface treatment composition
EP4364743A3 (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
TN2016000535A1 (en) Ppar compounds for use in the treatment of fibrotic diseases.
PH12017501082A1 (en) Calcium carbonate for plant protection
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
MX2017007188A (en) Antimycotic compound.
MX2017000487A (en) Drying process.
PH12016501096A1 (en) SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
MX2016013534A (en) Adsorbing and/or reduction of the amount of organic materials in an aqueous medium by using colloidal precipitated calcium carbonate.
MY181685A (en) Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
PH12017500613A1 (en) Improved peptide inhibitors of sodium channels
PH12017501897A1 (en) 2-thiopyrimidinones
MX2016009535A (en) Kit for treating a substrate.
MX2017016638A (en) Novel organoleptic compounds.
MY186883A (en) Calcium carbonate for particle boards
MA40027A (en) Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent
BR112016015578A2 (en) 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 AND TYPE 2 INHIBITORS
MX2017003020A (en) Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation.
MX2016009494A (en) Sulfur-containing phenol derivatives.